Annexon (ANNX) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Annexon (ANNX) over the past year, gaining 8.0% versus a loss of 27.4%. Over five years, DSGN leads with a -49.3% price change compared with -77.4% for ANNX. Annexon is the larger company by market cap ($591.4 million vs $577.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | DSGN |
|---|---|---|
| Share price | $3.10 | $9.02 |
| Market cap | $591.37M | $577.61M |
| 1-day change | -9.09% | -3.22% |
| YTD return | -38.25% | -3.84% |
| 1-year return | -27.40% | +8.02% |
| 5-year return | -77.37% | -49.27% |
| EPS (TTM) | $-1.01 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-206.69M | $-69.79M |
| 52-week high | $7.18 | $17.25 |
| 52-week low | $3.07 | $8.21 |
| Distance from 52-week high | -56.82% | -47.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.39% | +139.14% |
| Average volume | 3.36M | 554.69K |
| Shares outstanding | 190.76M | 64.04M |
| Employees | 97 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed ANNX by 35.4 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ANNX vs DSGN FAQ
Which is bigger, Annexon or Design Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $577.61M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, ANNX or DSGN?
DSGN returned +8.02% over the past 12 months, compared with -27.40% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.